Cargando…
Small molecule p300/catenin antagonist enhances hematopoietic recovery after radiation
There is currently no FDA approved therapeutic agent for ARS mitigation post radiation exposure. Here we report that the small molecule YH250, which specifically antagonizes p300/catenin interaction, stimulates hematopoiesis in lethally or sublethally irradiated mice. A single administration of YH25...
Autores principales: | Zhao, Yi, Wu, Kaijin, Nguyen, Cu, Smbatyan, Goar, Melendez, Elisabeth, Higuchi, Yusuke, Chen, Yibu, Kahn, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5423697/ https://www.ncbi.nlm.nih.gov/pubmed/28486541 http://dx.doi.org/10.1371/journal.pone.0177245 |
Ejemplares similares
-
CBP/Catenin Antagonist Safely Eliminates Drug Resistant Leukemia Initiating Cells
por: Zhao, Yi, et al.
Publicado: (2015) -
CBP/β-Catenin/FOXM1 Is a Novel Therapeutic Target in Triple Negative Breast Cancer
por: Ring, Alexander, et al.
Publicado: (2018) -
Nuclear receptor/Wnt beta-catenin interactions are regulated via differential CBP/p300 coactivator usage
por: Ono, Masaya, et al.
Publicado: (2018) -
Differentiation Therapy Targeting the β-Catenin/CBP Interaction in Pancreatic Cancer
por: Manegold, Philipp, et al.
Publicado: (2018) -
The Mode of Stem Cell Division Is Dependent on the Differential Interaction of β-Catenin with the Kat3 Coactivators CBP or p300
por: Lukaszewicz, Agnes I., et al.
Publicado: (2019)